Analysts expect Amneal Pharmaceuticals, Inc. to report revenue of 785.87 M for Q3 26, against a range of 735.48 M to 836.27 M. The most recent reported quarter, Q2 26, came in at 796.20 M, a 2.3% miss against the 815.10 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 702.47 M | 730.52 M | 695.42 M | 724.51 M | 784.51 M | 814.32 M | 722.52 M | 796.20 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 764.15 M | 771.05 M | 748.93 M | 740.55 M | 780.09 M | 807.79 M | 710.18 M | 876.78 M | 836.27 M | 907.80 M | 886.23 M | 863.91 M | 894.21 M | 992.65 M | 886.47 M | 1.01 B | ||||||||||
| Low Estimate | 701.16 M | 725.76 M | 626.76 M | 670.00 M | 728.83 M | 723.73 M | 659.86 M | 753.42 M | 735.48 M | 841.06 M | 764.57 M | 711.83 M | 762.53 M | 904.20 M | 761.06 M | 933.46 M | ||||||||||
| Consensus Estimate | 732.65 M | 748.41 M | 687.84 M | 705.27 M | 754.46 M | 765.76 M | 685.02 M | 815.10 M | 785.87 M | 874.43 M | 825.40 M | 787.87 M | 828.37 M | 948.43 M | 823.76 M | 973.08 M |
Analysts expect Amneal Pharmaceuticals, Inc. to report earnings per share of 0.22 for Q3 26, against a range of 0.20 to 0.24. The most recent reported quarter, Q2 26, came in at 0.30, a 30.4% beat against the 0.23 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.16 | 0.12 | 0.21 | 0.25 | 0.17 | 0.21 | 0.27 | 0.30 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 0.14 | 0.17 | 0.15 | 0.18 | 0.15 | 0.20 | 0.17 | 0.25 | 0.24 | 0.22 | 0.27 | 0.32 | 0.26 | 0.28 | 0.36 | 0.47 | ||||||||||
| Low Estimate | 0.12 | 0.15 | 0.13 | 0.16 | 0.13 | 0.18 | 0.15 | 0.21 | 0.20 | 0.20 | 0.25 | 0.30 | 0.22 | 0.26 | 0.32 | 0.39 | ||||||||||
| Consensus Estimate | 0.13 | 0.16 | 0.14 | 0.17 | 0.14 | 0.19 | 0.16 | 0.23 | 0.22 | 0.21 | 0.26 | 0.31 | 0.24 | 0.27 | 0.34 | 0.43 |
Pull Wall Street consensus for Amneal Pharmaceuticals, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=AMRX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "AMRX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=AMRX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();